MATCH - Myocardial de-Airing and Tissue preservation using carbon dioxide (CO2) with Humidification in patients undergoing open-chamber cardiac surgery

Effect of warm humidified carbon dioxide insufflation on pericardial tissue viability during open-chamber cardiac surgery. A randomized controlled trial.

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12618000473268

Acronym

MATCH

Enrollment

Registered

2018-04-03

Start date

2018-04-09

Completion date

2019-08-31

Last updated

2018-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

During open-heart surgery, gaseous micro-emboli (small gas bubbles) are commonly seen in the heart and bloodstream. This is thought to be associated with post-operative cognitive decline. To minimize this, it is common practice to insufflate the heart cavity with dry carbon dioxide (CO2) via a small tube. It is believed that CO2 causes less gaseous micro-emboli because it is denser and more soluble than air. However, dry and cold CO2 insufflation can cause tissue damage. A more sophisticated device, called the HumiGardTM system, is currently available in the market. It allows a continuous flow of warm and humidified CO2 to be insufflated via a gas diffuser into the heart cavity. In this study, we would like to test if warm and humidified CO2 will reduce the amount of tissue damage and also the number of micro-emboli travelling within the heart and to the brain, when compared to dry and cold CO2 insufflation.

Interventions

Intraoperative pericardial insufflation of 100% CO2 at 37 degrees C and 100% humidity during open-chamber cardiac surgery will be performed with the HumiGard™ Surgical Humidification system with VITA-diffuser (Fisher & Paykel Healthcare, NZ) to warm and humidify the CO2 being delivered. The diffuser will be placed by the surgeon.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used) (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Able to give informed consent Scheduled for open-chamber cardiac surgery

Exclusion criteria

Non-English speaking Contraindications to transoesophageal probe insertion, including severe oesophageal disease Emergency surgery

Outcome results